Search

Displaying results 4881 - 4890 of 5449 in total
  1. Drug

    Zeteletinib

    go.drugbank.com/drugs/DB21491
    Investigational

    Zeteletinib is under investigation in clinical trial NCT03780517 (Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors).

    Synonyms: Ret inhibitor ds-5010
  2. Drug

    1D09C3

    go.drugbank.com/drugs/DB05121
    Experimental

    HuCAL(R) library of human antibodies. 1D09C3 binds to certain cell surface receptors, selectively killing activated, proliferating MHC class II-positive tumor cells, which include those in B-cell and T-cell

  3. Drug

    CCX915

    go.drugbank.com/drugs/DB05159
    Experimental

    CCX915 is developed by ChemoCentryx which targets the chemokine receptor CCR2 and is in phase 1 of clinical trial for the treatment of Multiple Sclerosis and Neurologic Disorders. The CCR2 receptor is thought to be of central importance ...

  4. Drug

    VLTS-589

    go.drugbank.com/drugs/DB05430
    Investigational

    VLTS-589 consists of plasmid encoding the angiomatrix protein Del-1 in conjunction with poloxamer 188 for the treatment of peripheral vascular disease.

  5. Drug

    Mosedipimod

    go.drugbank.com/drugs/DB12592
    Investigational

    Mosedipimod has been used in trials studying the supportive care and treatment of Chemotherapy-induced Neutropenia.

  6. Drug

    CYP-001

    go.drugbank.com/drugs/DB15739
    Investigational

    CYP-001 is a mesenchymoangioblast (MCA)-derived mesenchymal stem cell (MSC) therapy that originates from the mesoderm. When activated with fibroblast growth factor-2 (FGF-2), MCAs create colonies with specific phenotypes. These cells are...

  7. Drug

    IDM-4

    go.drugbank.com/drugs/DB05438
    Experimental

    It is a monoclonal antibody-specific antigen that can selectively target cancer-affected cells by coupling with tumor cell-killing MAK cells, which are derived from the patient's own monocytes.

  8. Drug

    N,N,N-trimethylglycinium

    go.drugbank.com/drugs/DB04455
    Investigational

    (From Martindale, The Extra Pharmacopoeia, 30th ed, p1341)

  9. Drug

    Gataparsen

    go.drugbank.com/drugs/DB05141
    Investigational

    LY2181308 is investigated in clinical trials for treating solid tumors. LY2181308 is a solid. LY2181308 is directed against a molecular target called survivin. LY2181308 is known to target baculoviral IAP repeat-containing protein 5. LY2...

  10. Drug

    TBC-3711

    go.drugbank.com/drugs/DB05407
    Investigational

    TBC3711 is a next-generation endothelin antagonist that is being studied through oral and intravenous formulations by Encysive Pharmaceuticals.